Weekly Endocrinology Research Analysis
This week’s endocrinology literature emphasized metabolite-driven regulatory mechanisms and translational biomarker/therapeutic concepts alongside high-quality mechanistic work. Top papers described novel post-translational modifications linking amino-acid metabolism to adipose thermogenesis (AUH→PPARγ HMGylation), epigenetic control of pancreatic α-cell mass via CBP/p300–Slc7a2–mTORC1, and a lactylation-driven mitochondrial mechanism (LRPPRC K223/224) that connects hyperglycemia to cognitive de
Summary
This week’s endocrinology literature emphasized metabolite-driven regulatory mechanisms and translational biomarker/therapeutic concepts alongside high-quality mechanistic work. Top papers described novel post-translational modifications linking amino-acid metabolism to adipose thermogenesis (AUH→PPARγ HMGylation), epigenetic control of pancreatic α-cell mass via CBP/p300–Slc7a2–mTORC1, and a lactylation-driven mitochondrial mechanism (LRPPRC K223/224) that connects hyperglycemia to cognitive decline while yielding a circulating biomarker and a peptide therapeutic concept. Together these studies highlight new druggable nodes and circulating readouts that could shift early translational priorities.
Selected Articles
1. Leucine catabolic enzyme AUH regulates BAT thermogenesis via PPARγ HMGylation and RNA-binding function in male mice.
AUH promotes thermogenesis by producing HMG-CoA that HMGylates PPARγ at K386 to enhance UCP1 transcription and by stabilizing Ucp1 mRNA via RNA binding; AUH overexpression induces browning and protects male mice from diet-induced obesity, linking leucine catabolism to adipose thermogenic control.
Impact: Identifies a previously unrecognized metabolite-driven post-translational modification (PPARγ HMGylation) that directly controls thermogenesis and nominates AUH/PPARγ HMGylation as a novel obesity therapeutic axis.
Clinical Implications: Although preclinical, targeting AUH activity or modulating PPARγ HMGylation could be explored to enhance brown/beige fat thermogenesis and energy expenditure in obesity; sex-specific effects require evaluation.
Key Findings
- AUH-derived HMG‑CoA HMGylates PPARγ at lysine 386, enhancing transcriptional activity and UCP1 expression.
- AUH binds and stabilizes Ucp1 mRNA via RNA-binding function, providing a second mechanism to increase UCP1.
- AUH overexpression induces browning and protects male mice from high‑fat diet–induced obesity; human WAT AUH inversely correlates with adiposity.
2. CBP/p300 is critical for the expansion and maintenance of functional pancreatic α cell mass.
α cell–specific CBP/p300 deletion in mice causes hypoglucagonemia, hyperaminoacidemia, α-cell dedifferentiation and loss by impairing Slc7a2-mediated amino acid sensing and mTORC1 signaling via effects on H3K27 acetylation. CBP/p300 integrates amino-acid transport, epigenetic regulation, and proliferative signaling to maintain functional α-cell mass.
Impact: Reveals an epigenetic control node (CBP/p300) linking amino-acid transport (SLC7A2), histone acetylation and mTORC1 to α‑cell identity and proliferation, with implications for glucagon‑targeted diabetes strategies.
Clinical Implications: Suggests that preserving CBP/p300 activity or rescuing Slc7a2-dependent amino-acid sensing could modulate α-cell mass and affect responses to glucagon receptor–directed therapies; human validation is needed before clinical translation.
Key Findings
- α cell–specific CBP/p300 deletion caused hypoglucagonemia, hyperaminoacidemia, impaired proliferation, dedifferentiation and α‑cell loss.
- CBP/p300 knockout blocked glucagon receptor antibody–stimulated α‑cell proliferation and mTORC1 activation.
- Single-cell RNA-seq revealed downregulation of α‑cell identity genes and amino-acid transporters including Slc7a2; Slc7a2 loss impaired lysine-facilitated H3K27 acetylation and arginine-stimulated mTORC1.
3. Hyperglycemia impairs cognitive function by inducing mitochondrial damage through lactylation of LRPPRC at K223.
High glucose upregulates AARS2, inducing LRPPRC K223 lactylation in neurons, which weakens LRPPRC–SLIRP binding, reduces mitochondrial mRNA stability, causes mitochondrial dysfunction and neuronal apoptosis; a competitive peptide blocking LRPPRC lactylation improved cognition in diabetic mice, and plasma LRPPRC K224 lactylation predicted cognitive impairment in a prospective human cohort.
Impact: Elucidates a novel lactylation mechanism linking hyperglycemia to neurodegeneration and provides both a measurable circulating biomarker (LRPPRC K224 lactylation) and a peptide-based therapeutic proof-of-concept.
Clinical Implications: Plasma LRPPRC K224 lactylation could be developed for risk stratification of diabetes-related cognitive decline; inhibitors of LRPPRC lactylation (peptides or small molecules) warrant early-phase clinical testing.
Key Findings
- High glucose upregulates AARS2 and induces LRPPRC K223 lactylation, disrupting LRPPRC–SLIRP binding and decreasing mitochondrial mRNA stability.
- A competitive short peptide that blocks LRPPRC K223 lactylation ameliorated cognitive impairment in diabetic mice.
- Elevated plasma LRPPRC K224 lactylation independently predicted cognitive impairment in a large prospective cohort of patients with type 2 diabetes.